This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

February 2, 2023 | 1-Day Digital Conference

Digital Conference8:00AM EST // 1:00PM GMT // 2:00PM CET

Feb 2

Key Sessions

Jenny Zilberberg

A personalized whole tumor-derived cell-based autologous immunotherapy platform for the treatment of solid tumors

Imvax Inc

Sari Pesonen

PeptiCRAd platform as a novel intratumoral fusion immunotherapy targeting heterogeneous antigen profile of solid tumors

Valo Therapeutics

Karin Jooss

Neoantigen Immunotherapy For Solid Tumors – Molecular Responses and Clinical Benefit In End-Stage Patients – Moving Upstream

Gritstone Bio

Guilhem Richard

Distinguishing self-like neoantigens from non-self neoantigens for precision immunotherapies

EpiVax Therapeutics, Inc

Cancer Neoantigen VaccinesThursday, 2 February 2023 - EST/EDT (Eastern Daylight, GMT-4)

Showing 1 of 1 Streams

Main Stage

08:30 - 08:35

Opening Remarks

08:35 - 09:05

New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDC*line)

09:05 - 09:35

A personalized whole tumor-derived cell-based autologous immunotherapy platform for the treatment of solid tumors

09:35 - 10:05

Tumour Evolution: T Cell Evidence

10:05 - 10:20

Networking Break

10:20 - 10:50

PeptiCRAd platform as a novel intratumoral fusion immunotherapy targeting heterogeneous antigen profile of solid tumors

10:50 - 11:20

Neoantigen Immunotherapy For Solid Tumors – Molecular Responses and Clinical Benefit In End-Stage Patients – Moving Upstream

11:20 - 11:35

Networking Break

11:35 - 12:20

Market Trends and Why Is There No Vaccine Available?

12:20 - 12:50

An AI platform to predict clinically relevant T cell antigens, and its applications in therapy and biomarker discovery

12:50 - 13:20

Distinguishing self-like neoantigens from non-self neoantigens for precision immunotherapies

13:20 - 13:30

End of The Day Networking